BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

25718

531768

POLYMED

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

POLY MEDICURE LIMITED performance

Today’s low

Today’s high

₹ 2530.20 ₹ 2594.90
₹ 2574.00

52 week low

52 week high

₹ 1563.00 ₹ 3357.80
₹ 2574.00

Open Price

₹ 2588.30

Prev. Close

₹ 2588.30

Volume (Shares)

69680.00

Total traded value

₹ 1793.56

Upper Circuit

₹ 3105.90

Lower Circuit

₹ 2070.70

info

POLY MEDICURE LIMITED Share Price Update

As of the latest trading session, POLY MEDICURE LIMITED share price is currently at ₹ 2578.4, which is down by ₹ -9.90 from its previous closing. Today, the stock has fluctuated between ₹ 2530.20 and ₹ 2594.90. Over the past year, POLY MEDICURE LIMITED has achieved a return of 56.64 %. In the last month alone, the return has been 19.60 %. Read More...

POLY MEDICURE LIMITED fundamentals


  • Market cap (Cr)

    24,745.27

  • P/E Ratio (TTM)

    82.65

  • Beta

    0.83

  • Book Value / share

    254.10

  • Return on equity

    18.70%

  • EPS (TTM)

    31.11

  • Dividend yield

    0.11%

  • Net profit/quarter (Cr)

    85.15

info icon alternate text
  • Market cap (Cr)

    24,643.54

  • P/E Ratio (TTM)

    82.65

  • Beta

    0.73

  • Book Value / share

    254.10

  • Return on equity

    18.70%

  • EPS (TTM)

    31.11

  • Dividend yield

    0.11%

  • Net profit/quarter (Cr)

    85.15

info icon alternate text

POLY MEDICURE LIMITED Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 410.94
Operating Expense 319.30
Net Profit 85.15
Net Profit Margin (%) 20.72
Earnings Per Share (EPS) 8.48
EBITDA 137.35
Effective Tax Rate (%) 24.90
Particulars SEP 2024 (Values in Cr)
Revenue 402.47
Operating Expense 312.78
Net Profit 87.22
Net Profit Margin (%) 21.67
Earnings Per Share (EPS) 8.99
EBITDA 140.17
Effective Tax Rate (%) 25.40
Particulars JUN 2024 (Values in Cr)
Revenue 367.42
Operating Expense 288.18
Net Profit 72.30
Net Profit Margin (%) 19.67
Earnings Per Share (EPS) 7.53
EBITDA 118.04
Effective Tax Rate (%) 24.73
Particulars MAR 2024 (Values in Cr)
Revenue 360.93
Operating Expense 282.61
Net Profit 70.53
Net Profit Margin (%) 19.54
Earnings Per Share (EPS) 7.35
EBITDA 113.06
Effective Tax Rate (%) 24.94
Particulars DEC 2023 (Values in Cr)
Revenue 320.86
Operating Expense 255.34
Net Profit 61.46
Net Profit Margin (%) 19.15
Earnings Per Share (EPS) 6.41
EBITDA 100.97
Effective Tax Rate (%) 25.13
Particulars MAR 2024 (Values in Cr)
Revenue 1307.25
Operating Expense 1030.53
Net Profit 251.72
Net Profit Margin (%) 19.25
Earnings Per Share (EPS) 26.24
EBITDA 407.68
Effective Tax Rate (%) 24.83
Particulars MAR 2023 (Values in Cr)
Revenue 1068.05
Operating Expense 867.50
Net Profit 179.04
Net Profit Margin (%) 16.76
Earnings Per Share (EPS) 18.67
EBITDA 300.77
Effective Tax Rate (%) 24.39
Particulars MAR 2022 (Values in Cr)
Revenue 879.36
Operating Expense 723.37
Net Profit 146.02
Net Profit Margin (%) 16.60
Earnings Per Share (EPS) 15.23
EBITDA 250.87
Effective Tax Rate (%) 25.01
Particulars MAR 2021 (Values in Cr)
Revenue 747.38
Operating Expense 593.29
Net Profit 129.51
Net Profit Margin (%) 17.32
Earnings Per Share (EPS) 14.54
EBITDA 227.60
Effective Tax Rate (%) 25.30
Particulars MAR 2020 (Values in Cr)
Revenue 646.16
Operating Expense 542.96
Net Profit 92.38
Net Profit Margin (%) 14.29
Earnings Per Share (EPS) 10.47
EBITDA 178.72
Effective Tax Rate (%) 24.14
Particulars MAR 2024 (Values in Cr)
Book Value / Share 153.18
ROE % 19.05
ROCE % 23.44
Total Debt to Total Equity 0.12
EBITDA Margin 30.66
Particulars MAR 2023 (Values in Cr)
Book Value / Share 129.41
ROE % 15.39
ROCE % 18.95
Total Debt to Total Equity 0.12
EBITDA Margin 27.40
Particulars MAR 2022 (Values in Cr)
Book Value / Share 113.40
ROE % 14.27
ROCE % 17.26
Total Debt to Total Equity 0.13
EBITDA Margin 27.66
Particulars MAR 2021 (Values in Cr)
Book Value / Share 100.71
ROE % 19.40
ROCE % 21.67
Total Debt to Total Equity 0.25
EBITDA Margin 30.29
Particulars MAR 2020 (Values in Cr)
Book Value / Share 49.27
ROE % 23.49
ROCE % 24.38
Total Debt to Total Equity 0.45
EBITDA Margin 27.17
Particulars MAR 2024 (Values in Cr)
Book Value / Share 151.95
ROE % 18.70
ROCE % 23.12
Total Debt to Total Equity 0.11
EBITDA Margin 31.35
Particulars MAR 2023 (Values in Cr)
Book Value / Share 128.63
ROE % 15.49
ROCE % 19.21
Total Debt to Total Equity 0.11
EBITDA Margin 28.34
Particulars MAR 2022 (Values in Cr)
Book Value / Share 112.30
ROE % 14.38
ROCE % 17.54
Total Debt to Total Equity 0.12
EBITDA Margin 28.73
Particulars MAR 2021 (Values in Cr)
Book Value / Share 99.50
ROE % 18.72
ROCE % 21.37
Total Debt to Total Equity 0.23
EBITDA Margin 30.73
Particulars MAR 2020 (Values in Cr)
Book Value / Share 48.65
ROE % 22.84
ROCE % 24.24
Total Debt to Total Equity 0.43
EBITDA Margin 27.99
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 146.85
Total Assets 1858.67
Total Liabilities 1858.67
Total Equity 1470.05
Share Outstanding 95971417
Price to Book Ratio 10.46
Return on Assets (%) 13.89
Return on Capital (%) 15.74
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 177.63
Total Assets 1577.20
Total Liabilities 1577.20
Total Equity 1241.62
Share Outstanding 95944342
Price to Book Ratio 7.41
Return on Assets (%) 11.36
Return on Capital (%) 12.92
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 15.43
Total Assets 1376.83
Total Liabilities 1376.83
Total Equity 1087.48
Share Outstanding 95900342
Price to Book Ratio 8.45
Return on Assets (%) 10.64
Return on Capital (%) 12.08
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 29.56
Total Assets 1223.73
Total Liabilities 1223.73
Total Equity 965.57
Share Outstanding 95880567
Price to Book Ratio 8.22
Return on Assets (%) 11.10
Return on Capital (%) 12.36
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 25.35
Total Assets 767.32
Total Liabilities 767.32
Total Equity 434.82
Share Outstanding 88246980
Price to Book Ratio 4.84
Return on Assets (%) 12.49
Return on Capital (%) 15.92
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 136.94
Total Assets 1821.34
Total Liabilities 1821.34
Total Equity 1458.24
Share Outstanding 95971417
Price to Book Ratio 10.46
Return on Assets (%) 13.82
Return on Capital (%) 15.55
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 170.95
Total Assets 1537.76
Total Liabilities 1537.76
Total Equity 1234.12
Share Outstanding 95944342
Price to Book Ratio 7.41
Return on Assets (%) 11.64
Return on Capital (%) 13.08
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 8.31
Total Assets 1333.96
Total Liabilities 1333.96
Total Equity 1076.97
Share Outstanding 95900342
Price to Book Ratio 8.45
Return on Assets (%) 10.94
Return on Capital (%) 12.31
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 27.40
Total Assets 1187.41
Total Liabilities 1187.41
Total Equity 954.00
Share Outstanding 95880567
Price to Book Ratio 8.22
Return on Assets (%) 10.90
Return on Capital (%) 12.03
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 22.39
Total Assets 739.95
Total Liabilities 739.95
Total Equity 429.28
Share Outstanding 88246980
Price to Book Ratio 4.84
Return on Assets (%) 12.48
Return on Capital (%) 15.81
Particulars MAR 2024 (Values in Cr)
Net Income 344.26
Cash from Operations 340.38
Cash from Investing -240.93
Cash from Financing -20.15
Net change in Cash 4.99
Free Cash Flow 617.39
Particulars MAR 2023 (Values in Cr)
Net Income 237.49
Cash from Operations 248.91
Cash from Investing -179.24
Cash from Financing -12.50
Net change in Cash -0.69
Free Cash Flow 488.19
Particulars MAR 2022 (Values in Cr)
Net Income 195.24
Cash from Operations 170.92
Cash from Investing -85.33
Cash from Financing -35.33
Net change in Cash 2.80
Free Cash Flow 326.50
Particulars MAR 2021 (Values in Cr)
Net Income 180.05
Cash from Operations 163.35
Cash from Investing -435.58
Cash from Financing 316.94
Net change in Cash 0.09
Free Cash Flow 258.48
Particulars MAR 2020 (Values in Cr)
Net Income 125.72
Cash from Operations 164.23
Cash from Investing -107.25
Cash from Financing -20.50
Net change in Cash 0.53
Free Cash Flow 270.26
Particulars MAR 2024 (Values in Cr)
Net Income 334.89
Cash from Operations 329.84
Cash from Investing -237.02
Cash from Financing -17.31
Net change in Cash 1.76
Free Cash Flow 601.23
Particulars MAR 2023 (Values in Cr)
Net Income 236.82
Cash from Operations 254.66
Cash from Investing -189.18
Cash from Financing -7.89
Net change in Cash -0.25
Free Cash Flow 492.12
Particulars MAR 2022 (Values in Cr)
Net Income 194.71
Cash from Operations 173.12
Cash from Investing -88.71
Cash from Financing -39.71
Net change in Cash -2.16
Free Cash Flow 324.93
Particulars MAR 2021 (Values in Cr)
Net Income 173.38
Cash from Operations 160.53
Cash from Investing -434.41
Cash from Financing 318.91
Net change in Cash 0.90
Free Cash Flow 254.49
Particulars MAR 2020 (Values in Cr)
Net Income 121.78
Cash from Operations 162.48
Cash from Investing -105.67
Cash from Financing -22.25
Net change in Cash -1.01
Free Cash Flow 266.90
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 6962.05 76.41 13.35 100103.60 5690.80 / 7545.10
FORTIS MALAR HOSPITALS LIMITED 75.38 183.85 4.73 141.28 51.01 / 98.70
SHREE PACETRONIX LTD. 70.00 14.58 1.87 25.20 61.11 / 268.50
TRANSGENE BIOTEK LTD. 3.68 0.00 2.57 27.88 3.22 / 10.84
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 6962.05 83.30 12.22 100103.60 5690.80 / 7545.10
Surlux Diagnostic Ltd 1.40 0.84 0.13 0.49 0.00 / 0.00
CHENNAI MEENAKSHI MULTISPECIAL 32.25 0.00 -17.27 24.09 28.34 / 59.90
KOVAI MEDICAL CENTER & HOSPITA 5560.50 29.47 6.24 6083.19 3750.00 / 6400.00

POLY MEDICURE LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
2574.00 -0.55 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 2546.70
  • 26 Days 2355.00
  • 10 Days 2476.00
  • 50 Days 2328.40
  • 12 Days 2451.40
  • 100 Days 2352.30
  • 20 Days 2383.10
  • 200 Days 2284.70
2585.13 PIVOT

First Support

2561.37

First Resistance

2612.07

Second Support

2534.43

Second Resistance

2635.83

Third Support

2510.67

Third Resistance

2662.77

RSI

68.88

ADX

32.65

MACD

96.45

Williams % R

-5.49

Commodity Channel Index (CCI)

102.15

Date

2025-04-30

Week

64818.00

Same Day

47308.00

Month

49704.00

1 Year

0.84

3 Year

0.61

Over 1 Month

19.60%

down

Over 1 Year

56.64%

down

Over 3 Months

11.70%

down

Over 3 Years

42.61%

down

Over 6 Months

-7.75%

down

Over 5 Years

62.52%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

POLY MEDICURE LIMITED shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
14.14%
Promoter Holdings
62.43%
FII
11.45%
DII
11.95%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Ezekiel Global Business Solutions Llp 1.236132E7 (12.2%) Shareholding of Promoter and Promoter Group
Rishi Baid 9716356.0 (9.59%) Shareholding of Promoter and Promoter Group
Zetta Matrix Consulting Llp 8322160.0 (8.21%) Shareholding of Promoter and Promoter Group
Himanshu Baid 7907624.0 (7.8%) Shareholding of Promoter and Promoter Group
Himanshu Baid (huf) 3839200.0 (3.79%) Shareholding of Promoter and Promoter Group
Vcb Trading Llp 3541144.0 (3.49%) Shareholding of Promoter and Promoter Group
Quant Mutual Fund - Quant Small Cap Fund 3393876.0 (3.35%) Public Shareholding
Jai Polypan Pvt. Ltd. 3302000.0 (3.26%) Shareholding of Promoter and Promoter Group
Smt. Mukulika Baid 3062400.0 (3.02%) Shareholding of Promoter and Promoter Group
Rishi Baid (huf) 2780000.0 (2.74%) Shareholding of Promoter and Promoter Group
Jugal Kishore Baid 2279376.0 (2.25%) Shareholding of Promoter and Promoter Group
Axis Max Life Insurance Limited A/c Smart Innovation Fund 1965392.0 (1.94%) Public Shareholding
Nirmala Vinodkumar Daga 1827326.0 (1.8%) Public Shareholding
Vishal Baid 1681360.0 (1.66%) Shareholding of Promoter and Promoter Group
Smallcap World Fund, Inc 1682631.0 (1.66%) Public Shareholding
Uti Nifty Midsmallcap 400 Momentum Quali Ty 100 Index Fund 1645298.0 (1.62%) Public Shareholding
Varun Daga 1558224.0 (1.54%) Public Shareholding
Shreans Daga 1445122.0 (1.43%) Public Shareholding
Lighthouse India Fund Iv Aif 1385760.0 (1.37%) Public Shareholding
Shaily Baid 1188000.0 (1.17%) Shareholding of Promoter and Promoter Group
Shireen Baid 1121600.0 (1.11%) Shareholding of Promoter and Promoter Group
Neha Baid 1024000.0 (1.01%) Shareholding of Promoter and Promoter Group
Dhruv Baid 360000.0 (0.36%) Shareholding of Promoter and Promoter Group
Arham Baid 280000.0 (0.28%) Shareholding of Promoter and Promoter Group
Aaryaman Baid 280000.0 (0.28%) Shareholding of Promoter and Promoter Group
Madhu Kothari 151200.0 (0.15%) Shareholding of Promoter and Promoter Group
Vinay Kothari 56000.0 (0.06%) Shareholding of Promoter and Promoter Group
Polycure Martech Limited 10000.0 (0.01%) Shareholding of Promoter and Promoter Group
Bhupendra Raj Mehta 1600.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

POLY MEDICURE LIMITED corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
21 Sep 2023 3.0 Final 22 Sep 2023 Equity shares
16 Sep 2022 2.5 Final 19 Sep 2022 Equity shares
16 Sep 2021 2.5 Final 17 Sep 2021 Equity shares
27 Feb 2020 2.0 Interim 29 Feb 2020 Equity shares
13 Sep 2019 2.0 Final 17 Sep 2019 Equity shares
18 Sep 2018 2.0 Final 20 Sep 2018 Equity shares
20 Sep 2017 0.5 Final 22 Sep 2017 Equity shares
15 Feb 2017 1.0 Interim 2 16 Feb 2017 Equity shares
11 Nov 2016 1.0 Interim 15 Nov 2016 Equity shares
19 Sep 2016 0.5 Final 21 Sep 2016 Equity shares
17 Mar 2016 2.5 Interim 18 Mar 2016 Equity shares
18 Sep 2015 2.5 Final 22 Sep 2015 Equity shares
15 Sep 2014 4.0 Final 17 Sep 2014 Equity shares
19 Sep 2013 2.0 Final 23 Sep 2013 Equity shares
13 Sep 2012 3.0 Final 17 Sep 2012 Equity shares
25 Aug 2011 3.0 Final 27 Aug 2011 Equity shares
24 Aug 2010 2.5 Final 26 Aug 2010 Equity shares
21 Aug 2009 2.5 Final 25 Aug 2009 Equity shares
23 Aug 2007 2.5 Final 27 Aug 2007 Equity shares
06 Sep 2005 0.0 Final 09 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
28 Mar 2017 24 Mar 2017 1:1
10 Jul 2013 09 Jul 2013 1:1
29 Mar 2010 26 Mar 2010 1:1
Ex-Date Old FV NEW FV Record Date
02 Feb 2015 10.0 5.0 03 Feb 2015
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
21 Sep 2023 3.0 Final 22 Sep 2023 Equity shares
16 Sep 2022 2.5 Final 19 Sep 2022 Equity shares
16 Sep 2021 2.5 Final 17 Sep 2021 Equity shares
27 Feb 2020 2.0 Interim 29 Feb 2020 Equity shares
13 Sep 2019 2.0 Final 17 Sep 2019 Equity shares
18 Sep 2018 2.0 Final 20 Sep 2018 Equity shares
20 Sep 2017 0.5 Final 22 Sep 2017 Equity shares
15 Feb 2017 1.0 Interim 2 16 Feb 2017 Equity shares
11 Nov 2016 1.0 Interim 15 Nov 2016 Equity shares
19 Sep 2016 0.5 Final 21 Sep 2016 Equity shares
17 Mar 2016 2.5 Interim 18 Mar 2016 Equity shares
18 Sep 2015 2.5 Final 22 Sep 2015 Equity shares
15 Sep 2014 4.0 Final 17 Sep 2014 Equity shares
19 Sep 2013 2.0 Final 23 Sep 2013 Equity shares
13 Sep 2012 3.0 Final 17 Sep 2012 Equity shares
25 Aug 2011 3.0 Final 27 Aug 2011 Equity shares
24 Aug 2010 2.5 Final 26 Aug 2010 Equity shares
21 Aug 2009 2.5 Final 25 Aug 2009 Equity shares
23 Aug 2007 2.5 Final 27 Aug 2007 Equity shares
06 Sep 2005 0.0 Final 09 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
28 Mar 2017 24 Mar 2017 1:1
10 Jul 2013 09 Jul 2013 1:1
29 Mar 2010 26 Mar 2010 1:1
Ex-Date Old FV NEW FV Record Date
02 Feb 2015 10.0 5.0 03 Feb 2015

POLY MEDICURE LIMITED Share Price

Poly Medicure Limited was incorporated on March 30, 1995. The Company is a manufacturer/producer of Medical Devices. It manufactures and supply, in India and internationally, a diverse portfolio of medical devices in the product verticals of infusion therapy, oncology, anesthesia and respiratory care, urology, gastroenterology, blood management and blood collection, surgery and wound drainage, dialysis, central venous access catheters, veterinary medical devices and others.

The Company's product portfolio comprises of more than 130 SKUs of medical devices in the product verticals of infusion therapy, oncology, anesthesia and respiratory care, urology, gastroenterology, blood management and blood collection, surgery and wound drainage, dialysis, central venous access catheters, veterinary medical devices, and others. It currently operate 10 manufacturing facilities across India, China, Egypt and Italy. In India, it operate 7 manufacturing facilities, four of which are situated at Faridabad (Haryana), and 2 in Jaipur (Rajasthan) and 1 in Haridwar (Uttarakhand). It operate 1 manufacturing facility in China through its wholly owned subsidiary Poly Medicure (Laiyang) Company Limited.

The Company started commercial production by April' 97 with an installed capacity of Medical Disposables (16500000 Nos ) and Cold/Hot Therapy Packs (500000 Nos).

During the year 1997-98, the company produced 51.06 lac nos. of Medical Disposables which constitute 42.60% of the installed capacity utilisation. The company exported products of the value Rs. 50.28 lacs. The Company has been registered as an ISO 9002 company by SGS Yarsley International Certification Service Limited, United Kingdom.

During the year 2003, the Company entered into a Joint Venture arrangement for putting up a plant in Egypt for manufacturing of various Medical Disposables. It has subscribed to 23% (6,90,000 Egyptian Pounds equivalent to Rs. 71,07,000/-) of the share capital of the Joint Venture Entity. The Overseas Joint Venture is expected to commence commercial production during the current financial year.

During the year 2005, it expanded installed capacity from 1000 lacs nos. to 1200 lacs nos. of Medical Disposables. The Company successfully implemented Quality Management System and has been accredited by SGS Yarsley International Certification Services, United Kingdom with ISO 9001:2000, ISO 13488:1996 and CE mark for some of its products. For the rest of the products, it has been accredited CE mark by DNV, Norway thus making the entire product range match up to International Quality Standards.

In 2008, the Company's manufacturing unit located at Haridwar, Uttarakhand commenced its commercial operations.

In 2010, the Company received Silver Patent Award by Department of Pharmaceutical Ministry of Chemicals and Fertilizers, Government of India and Pharmaceuticals Export Promotion Council in recognition of commendable contribution in Medical devices patent Category. It was also awarded by India Brand Equity Foundation (IBEF), in certificate of excellence in recognition of exemplary growth and sustainable success.

As of March 31, 2015, Company had over 100 varieties of disposable medical devices, including veterinary disposable devices.

In 2015, the manufacturing facility in Jaipur, Rajasthan commenced commercial operations.

During the year 2018, the Company's wholly owned subsidiary, Poly Medicure B.V. Netherlands acquired 82% stake in Plan 1 Health s.r.l., an Italy-based manufacturing company. Apart from this, it started manufacturing operations of new plant at IIT, in Faridabad effective from 28th February, 2018.

The Company received 'Top Exporter Award' by The Plastics Export Promotion Council, Dept of Commerce, Govt. of India, 'Star Performer Award' by EEPC India Regional Award (Northern) for Export Excellence, 'Dare to Dream Award' by ZEE Business in the category of emerging Company of the year and 'Export Excellence Award' by FIA (Faridabad Industries Association), Haryana for the year 2018-19. The Company received the 'Medical Device Company of the Year 2018', award from Department of Pharmaceuticals, Government of India - Biggest recognition and Achievement since inception of the company. The award was conferred based on Company's export performance, R&D efforts and New Product launches. It was awarded 'Industrial Innovation Award' by Confederation of Indian Industries (CII) on 18th December, 2019 for securing place among the top 25 innovative companies in 2019.

The Company received the 'Forbes Asia Best under a Billion' Award in 2020 as the region's top 200 small and mid-sized companies.

The Company currently operate eight manufacturing facilities across India, China, Egypt and Italy. In India, it operate five manufacturing facilities, three of which are situated at Faridabad (Haryana), and one each in Jaipur (Rajasthan) and Haridwar (Uttarakhand). In addition, it is in the process of expanding the manufacturing capacities at facilities situated in Faridabad (Haryana) and Jaipur (Rajasthan).

Apart from this, the Company operate one manufacturing facility in China through its wholly-owned subsidiary Poly Medicure (Liayang) Company Limited that is certified to be compliant with Korea Good Manufacturing Practices by the Korea Food and Drug Administration, Ministry of Food and Drug Safety and has been accredited with a EC certificate for quality assurance system and EN ISO 13485:2016 for its quality management system. In addition, it operates one manufacturing facility in Assuit, Egypt, through our associate Ultra for Medical Products that is accredited with EC certificates or quality assurance system. It operate one manufacturing facility in Italy through step-down subsidiary Plan1 Health S.R.L., which is accredited with EC certification for quality assurance system and EN 13485:2016 for its quality management system by DEKRA Certification B.V. Netherlands.

The Company use different technologies for manufacturing different medical devices, including injection molding, extrusion, insert molding, blow molding, ultrasonic welding, UV bonding and laser welding and has expertise in handling different kind of specialized plastic materials. The manufacturing of components takes place on highly advanced PLC controlled plastic injection molding machines by using hot runner system or runner less mold technology, which is a clean technology and generates minimal scrap. Tubes are produced on highly accurate extruders with good yield. Its assembly machines are built-in with poka-yoke features and vision inspection systems. The manufacturing facility is equipped with CNC controlled machines which enable accurate and efficient control over fabrication of molds. It further employ kaizen or lean manufacturing technology for cycle time reduction in various manufacturing processes.

Its manufacturing process comprises of using raw materials in molding or tubing through extruders, following which components are assembled and samples are tested. The products are packed using a blister packing machine in duplex or correlated boxes and the final products undergo sterilization and quality checks. These include, automated arms installed at assembly machines, which are designed and programmed for specific assembly functions that may be deployed for various product variants. The manufacturing equipment is also supported by Servo' systems that enable precise machine movements that improves accuracy in processes and limits generation of scrap.

The Company operate the R&D Centre at Faridabad, Haryana which is approved by DSIR. Our R&D efforts are primarily focused on developing new products within existing product verticals as well as introduce products to enter into new product verticals, particularly focusing on fluid management within non-communicable diseases segment, including oncology, nephrology and cardiology, and further improving existing processes and production cost efficiency.

As of March 31, 2021, the Company had over 130 SKUs of medical devices. Besides this, it supplied products to over 110 countries, in Europe, Africa, Americas, Australia, and Asia through a network of over 220 distributors in these jurisdictions.

The Company's Indian and International manufacturing facilities have been accredited with several international quality certifications. All manufacturing facilities have been accredited with the EC certificates for quality assurance systems and EN ISO 13485:2016 certifications. Further, Faridabad Facilities and Haridwar Facility, have also been accredited with management system certificates for compliance with ISO 9001:2015.

In 2023-24, the Company expanded into cardiology and launched a Critical Care Division for focusing on products used in intensive care. The distribution network with a pan-India presence included 506 distributors in 2024. The Company set up 2 new manufacturing units in Faridabad, Haryana and Jaipur in Rajasthan, by expanding its existing Faridabad Facility III and Jaipur I Facility.

Parent organization Indian Private
NSE symbol POLYMED
Founded 1995
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Poly Medicure Ltd?

Answer Field

The share price of Poly Medicure Ltd for NSE is ₹ 2578.4 and for BSE is ₹ 2567.8.

What is the Market Cap of Poly Medicure Ltd?

Answer Field

The market cap of Poly Medicure Ltd for NSE is ₹ 2,47,45.27 Cr. and for BSE is ₹ 2,46,43.54 Cr. as of now.

What is the 52 Week High and Low of Poly Medicure Ltd?

Answer Field

The 52 Week High and Low of Poly Medicure Ltd for NSE is ₹ 3357.80 and ₹ 1563.00 and for BSE is ₹ 3350.00 and ₹ 1565.00.

How to Buy Poly Medicure Ltd share?

Answer Field

You can trade in Poly Medicure Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Poly Medicure Ltd?

Answer Field

The 1 year returns on the stock has been 56.64%.

What is the Current Share Price of Poly Medicure Ltd?

Answer Field

Poly Medicure Ltd share price is for NSE ₹ 2578.4 & for BSE ₹ 2567.8 as on Apr 30 2025 03:29 PM.

What is the Market Cap of Poly Medicure Ltd Share?

Answer Field

The market cap of Poly Medicure Ltd for NSE ₹ 2,47,45.27 & for BSE ₹ 2,46,43.54 as on Apr 30 2025 03:29 PM.

What is the P/E Ratio of Poly Medicure Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM the price-to-earnings (PE) ratio for Poly Medicure Ltd share is 82.65.

What is the PB ratio of Poly Medicure Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM, the price-to-book (PB) ratio for Poly Medicure Ltd share is 254.10.

How to Buy Poly Medicure Ltd Share?

Answer Field

You can trade in Poly Medicure Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Poly Medicure Ltd Share on Bajaj Broking App?

Answer Field

To buy Poly Medicure Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Poly Medicure Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|